CGEM

12.20

1.50% 0.18

Handel nachbörslich: 12.55 0.35 +2.87%

Cullinan Therapeutics Inc (CGEM)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$12.02

Offen:

$11.75

24-Stunden-Volumen:

545.76K

Relative Volume:

1.12

Marktkapitalisierung:

$710.38M

Einnahmen:

Nettoeinkommen (Verlust:

$-153.16M

KGV:

-3.6202

EPS:

-3.37

Netto-Cashflow:

$-134.48M

1W Leistung:

+2.78%

1M Leistung:

-9.29%

6M Leistung:

-30.05%

1J Leistung:

+19.73%

1-Tages-Spanne:

$11.75

$12.28

1-Wochen-Bereich:

$11.68

$12.95

52-Wochen-Spanne:

$10.00

$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Firmenname

Cullinan Therapeutics Inc

Sektor

Healthcare (1198)

Branche

Biotechnology (678)

Telefon

617-410-4650

Adresse

ONE MAIN STREET, CAMBRIDGE

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CGEM's Discussions on Twitter

Vergleichen Sie CGEM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CGEM Cullinan Therapeutics Inc	12.20	710.38M	0	-153.16M	-134.48M	-3.69
VRTX Vertex Pharmaceuticals Inc	399.35	102.84B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	702.59	77.21B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	619.96	37.07B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	236.01	30.44B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	112.58	26.99B	3.30B	-501.07M	1.03B	-2.1146

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-05-01	Eingeleitet	Stifel	Buy
2024-04-15	Eingeleitet	William Blair	Outperform
2024-02-15	Eingeleitet	Wedbush	Outperform
2023-06-15	Eingeleitet	TD Cowen	Outperform
2022-11-21	Eingeleitet	BTIG Research	Buy
2021-04-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-02-02	Eingeleitet	Evercore ISI	Outperform
2021-02-02	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-02	Eingeleitet	SVB Leerink	Outperform
2021-02-01	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

05:20 AM

Don't Ignore The Insider Selling In Cullinan Therapeutics - Simply Wall St

05:20 AM

01:56 AM

Financial Comparison: Genfit (NASDAQ:GNFT) vs. Cullinan Therapeutics (NASDAQ:CGEM) - Defense World

01:56 AM

Dec 29, 2024

Geode Capital Management LLC Acquires 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 29, 2024

Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Dec 29, 2024

Dec 27, 2024

Cullinan Therapeutics CEO sells shares worth $99,708 - Investing.com

Dec 27, 2024

Dec 23, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of “Buy” by Analysts - Defense World

Dec 23, 2024

Barclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 23, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Dec 23, 2024

Dec 22, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.6% Higher – Here’s Why - Defense World

Dec 22, 2024

Dec 21, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street Corp - Defense World

Dec 21, 2024

State Street Corp Buys 396,034 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 21, 2024

Dec 20, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat

Dec 20, 2024

Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia

Dec 20, 2024

Cullinan Therapeutics chief scientific officer sells $53,547 in stock By Investing.com - Investing.com Canada

Dec 20, 2024

Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com

Dec 20, 2024

Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com

Dec 20, 2024

Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India

Dec 20, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat

Dec 20, 2024

Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Dec 20, 2024

Dec 19, 2024

Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 19, 2024

Dec 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat

Dec 18, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.19 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Dec 18, 2024

Dec 16, 2024

Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of Stock - MarketBeat

Dec 16, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat

Dec 16, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by The Manufacturers Life Insurance Company - Defense World

Dec 16, 2024

Dec 12, 2024

Charles Schwab Investment Management Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 12, 2024

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Dec 12, 2024

Dec 05, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Purchased by RTW Investments LP - MarketBeat

Dec 05, 2024

Dec 04, 2024

Patient Square Capital LP Acquires New Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Dec 04, 2024

Dec 03, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Holocene Advisors LP - MarketBeat

Dec 03, 2024

Dec 02, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC - MarketBeat

Dec 02, 2024

Nov 30, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LP - MarketBeat

Nov 30, 2024

Nov 28, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $31.67 - MarketBeat

Nov 28, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Average Target Price from Brokerages - MarketBeat

Nov 28, 2024

Nov 20, 2024

Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks

Nov 20, 2024

What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat

Nov 20, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Nov 20, 2024

Nov 15, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat

Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com

Nov 15, 2024

CGEMCullinan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

Biotechnology Value Fund L.P. Expands Stake in Cullinan Therapeu - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada

Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial - Investing.com

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian

Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.

Nov 14, 2024

Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia

Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India

Nov 08, 2024

Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com

Nov 08, 2024

Nov 07, 2024

Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 07, 2024